Get the Stockscreener App
171.34
1.13%
-1.96
After Hours:
171.40
0.06
+0.04%
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca Plc stock is traded at $171.34, with a volume of 2.26M.
It is down -1.13% in the last 24 hours and down -9.64% over the past month.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
See More
Previous Close:
$173.30
Open:
$170.315
24h Volume:
2.26M
Relative Volume:
1.00
Market Cap:
$265.73B
Revenue:
$60.48B
Net Income/Loss:
$10.40B
P/E Ratio:
51.46
EPS:
3.3297
Net Cash Flow:
$8.05B
1W Performance:
+1.82%
1M Performance:
-9.64%
6M Performance:
+84.69%
1Y Performance:
+123.71%
1-Day Range:
$169.85
$171.89
1-Week Range:
$167.79
$175.03
52-Week Range:
$72.89
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Name
Astrazeneca Plc
Sector
Industry
Phone
-
Address
-
Compare AZN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
171.34 | 263.09B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,154.97 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
255.82 | 640.91B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
257.41 | 453.91B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
129.79 | 322.95B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
158.44 | 296.72B | 54.66B | 13.58B | 16.05B | 7.0171 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | Citigroup | Buy |
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca Plc Stock (AZN) Latest News
Judge Dismisses AstraZeneca’s Bid To Stop Maine Pharmacy Law - Bloomberg Law News
AstraZeneca's drug pipeine is splitting opinion among City analysts - Proactive Investors
ASTRAZENECA : DZ Bank gives a Buy rating - marketscreener.com
ASTRAZENECA : Gets a Buy rating from Berenberg - marketscreener.com
ASTRAZENECA : Gets a Buy rating from Goldman Sachs - marketscreener.com
ASTRAZENECA : UBS remains its Buy rating - marketscreener.com
AstraZeneca reports Phase III results for Ultomiris and Sone-Ve - Clinical Trials Arena
AstraZeneca Stock: What We Thought of Earnings - Morningstar
AstraZeneca Kept at Buy as Berenberg Notes 'Upbeat' Q2 Earnings Call - marketscreener.com
AstraZeneca PLC (AZN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
AZN Q2 FY2026 earnings call - finance.biggo.com
AstraZeneca PLC (AZN) Stock Forecasts - Yahoo Finance
AstraZeneca PLC (AZN) Q2 2026 Earnings Call Highlights: Strong Oncology and Rare Disease Growth ... - Yahoo Finance
AZN Q2 Earnings and Sales Beat, Key Drugs Offset Generic Pressure - TradingView
AstraZeneca’s MONTEROSA Study Tracks Real World Outcomes for STRIDE in Liver Cancer - TipRanks
AstraZeneca: Q2 2026 Results Were All Right, But Farxiga Poses Risks (NYSE:AZN) - Seeking Alpha
AstraZeneca PLC (AZN) Investigation: Bronstein, Gewirtz & Grossma - The National Law Review
AstraZeneca rallies Monday, outperforms market - MarketWatch
AstraZeneca PLC (AZN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
AstraZeneca quarterly net profit rises 2% on strong cancer drug sales - Yahoo Finance UK
Astrazeneca Rises on Profit Beat; Paramount Pauses WBD Deal | Stock Movers - marketscreener.com
AstraZeneca: In line Q2; correction of late is an entry point - marketscreener.com
Dow Jumps Over 400 Points; AstraZeneca Shares Rise After Q2 Earnings - Benzinga
AstraZeneca drug prices evolving in response to Trump policy, executive says - Reuters
AstraZeneca PLC Stock Analysis: Q2 Earnings Beat vs Bearish Trend - The Cryptonomist
Astrazeneca (AZN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
AstraZeneca says adjusting drug pricing over Trump policies By Investing.com - Investing.com Nigeria
Astrazeneca Q2 Earnings Call Highlights - Yahoo Finance
What's Going on With AstraZeneca Stock Monday?AstraZeneca (NYSE:AZN) - Benzinga
AstraZeneca (NASDAQ: AZN) lifts H1 profit and backs 2026 outlook - Stock Titan
AstraZeneca oncology growth continues despite product setback - Investors' Chronicle
AstraZeneca profit rises on strong cancer drug sales - Yahoo Finance
AstraZeneca Sees 2030 Goal on Track as Cancer Drugs Drive Growth - WSJ
ASTRAZENECA : Jefferies gives a Buy rating - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Encourages AstraZeneca PLC (AZN) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Mixed Ultomiris HSCT-TMA results at AstraZeneca (NASDAQ: AZN) spur paediatric filings - Stock Titan
AstraZeneca PLC 2026 Q2ResultsEarnings Call Presentation (NYSE:AZN) 2026-07-27 - Seeking Alpha
AstraZeneca to Acquire Worldwide Rights to Lung Cancer Drug for $600M - Stock Titan
AstraZeneca sales boosted by soaring demand for cancer treatments - Yahoo Finance UK
AstraZeneca (NASDAQ: AZN) Phase III Sone-Ve data show gastric survival gain - Stock Titan
ASTRAZENECA PLC ORD SHS $0.25 (AZN.L) Q2 FY2026 earnings call transcript - Yahoo Finance
AstraZeneca stock edges up on earnings beat despite revenue miss - Investing.com
AstraZeneca Q2 Core Earnings, Revenue Rise; Interim Dividend Raised - marketscreener.com
AstraZeneca PLC Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
AstraZeneca reiterates guidance after topping Q2 profit expectations; shares up - Investing.com Nigeria
AstraZeneca PLC (AZN) Stock Analysis: Exploring a 26% Potential Upside and Strong Buy Ratings - DirectorsTalk Interviews
Market Open: Vodafone raises guidance, AstraZeneca H1 growth - Yahoo Finance UK
AstraZeneca CFO says AI is not expected to lead to job cuts - marketscreener.com
AstraZeneca sales rise as demand for cancer treatments grow - Yahoo Finance UK
AstraZeneca Logs Higher First-half Profit on Strong Oncology, Rare Disease Drugs Sales; Outlook Maintained - marketscreener.com
AstraZeneca’s Cancer Medicines Spur Profit Growth - Bloomberg
Astrazeneca Plc Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.25%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):